Affordable SARS-CoV-2 protein vaccines for the pandemic endgame.

The astonishing speed with which coronavirus disease 2019 (COVID-19) vaccines were developed is nothing short of a scientific triumph. The COVID-19 Vaccines Global Access Scheme (COVAX) was established to facilitate global COVID-19 vaccine distribution; however, COVAX is underfunded, has struggled to secure enough vaccine doses and has failed to meet many key targets. When combined with an affordable adjuvant, a sub-dollar per dose COVID-19 vaccine is feasible; this contrasts with the high cost of mRNA vaccines and complexities around their manufacture and access to intellectual property[12]. It is clear that global vaccine production and supply need to be increased, ideally through the building of vaccine manufacturing and distribution capacity in LMICs. [Extracted from the article]